The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 27, 2007
Filed:
Mar. 27, 2003
Sherri M. Brown, Chesterfield, MO (US);
Tedd D. Elich, Ballwin, MO (US);
Gregory R. Heck, Crystal Lake Park, MO (US);
Ganesh M. Kishore, St. Louis, MO (US);
Eugene W. Logusch, Chesterfield, MO (US);
Sherry J. Logusch, Chesterfield, MO (US);
Kenneth J. Piller, St. Louis, MO (US);
Sudabathula Rao, St. Louis, MO (US);
Joel E. Ream, St. Louis, MO (US);
Scott R. Baerson, St. Louis, MO (US);
Sherri M. Brown, Chesterfield, MO (US);
Tedd D. Elich, Ballwin, MO (US);
Gregory R. Heck, Crystal Lake Park, MO (US);
Ganesh M. Kishore, St. Louis, MO (US);
Eugene W. Logusch, Chesterfield, MO (US);
Sherry J. Logusch, Chesterfield, MO (US);
Kenneth J. Piller, St. Louis, MO (US);
Sudabathula Rao, St. Louis, MO (US);
Joel E. Ream, St. Louis, MO (US);
Scott R. Baerson, St. Louis, MO (US);
Monsanto Technology LLC, St. Louis, MO (US);
Abstract
Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase. 3-β hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing a RNA or protein product which suppresses the gibberellin biosynthetic pathway sequence, diverts substrates from the pathway or degrades pathway substrates or products. The sequence is preferably a copalyl diphosphate synthase sequence, a 3β-hydroxylase sequence, a 2-oxidase sequence, a phytoene synthase sequence, a C20-oxidase sequence, and a 2β,3β-hydroxylase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.